Pharsight

Glyxambi is owned by Boehringer Ingelheim.

Glyxambi contains Empagliflozin; Linagliptin.

Glyxambi has a total of 13 drug patents out of which 0 drug patents have expired.

Glyxambi was authorised for market use on 30 January, 2015.

Glyxambi is available in tablet;oral dosage forms.

Glyxambi can be used as method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin, method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea); method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin), method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin.

The generics of Glyxambi are possible to be released after 11 June, 2034.

Application	Filing Date	Opposition Party	Legal Status
EP14715578A	2019-08-14	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP14715578A	2019-08-14	Stada-Arzneimittel Aktiengesellschaft	Granted and Under Opposition
EP14715578A	2019-08-14	Generics (U.K.) Limited	Granted and Under Opposition
EP14715578A	2019-08-14	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP14715578A	2019-08-14	Gillard, Richard Edward	Granted and Under Opposition
EP14715578A	2019-08-12	EGIS Gyógyszergyár Zártkörüen Müködö Részvénytársaság	Granted and Under Opposition
EP14715578A	2019-08-09	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP14715578A	2019-08-02	KRKA, d.d., Novo mesto	Granted and Under Opposition
EP08787264A	2017-07-12	STADA Arzneimittel AG	Granted and Under Opposition
EP08787264A	2017-07-12	Hexal AG	Granted and Under Opposition
EP08787264A	2017-07-12	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP08787264A	2017-07-11	Generics (U.K.) Limited	Granted and Under Opposition
EP10175188A	2015-12-11	Galenicum Health S.L.	Revoked
EP10175188A	2015-12-11	Generics (UK) Limited	Revoked
EP10175188A	2015-12-10	STADA Arzneimittel AG	Revoked
EP10175188A	2015-12-10	Hexal AG	Revoked
EP10175188A	2015-12-10	Teva Pharmaceutical Industries LTD.	Revoked
EP10175638A	2015-07-08	Generics [UK] Limited (trading as Mylan)	Revoked
EP10175638A	2015-07-08	STADA Arzneimittel AG	Revoked
EP10175638A	2015-07-07	Hexal AG	Revoked
EP10175638A	2015-07-07	Teva Pharmaceutical Industries Ltd.	Revoked
EP07728723A	2015-01-05	Hexal AG	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US9173859	August, 2016	Terminated-Denied	Boehringer Ingelheim Pharmaceuticals Inc.	Mylan Pharmaceuticals Inc.
US8673927	August, 2016	Terminated-Adverse Judgment	Boehringer Ingelheim Pharmaceuticals Inc.	Mylan Pharmaceuticals Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	May, 2025 (1 year, 10 months from now)
US7713938	BOEHRINGER INGELHEIM	Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	Apr, 2027 (3 years from now)
US7579449	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Aug, 2028 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (2 months from now)
US8178541	BOEHRINGER INGELHEIM	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions	Aug, 2023 (2 months from now)
US8883805	BOEHRINGER INGELHEIM	Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines	Nov, 2025 (2 years from now)
US8673927	BOEHRINGER INGELHEIM	Uses of DPP-IV inhibitors	May, 2027 (3 years from now)
US9173859	BOEHRINGER INGELHEIM	Uses of DPP IV inhibitors	May, 2027 (3 years from now)
US11033552	BOEHRINGER INGELHEIM	DPP IV inhibitor formulations	May, 2027 (3 years from now)
US8551957	BOEHRINGER INGELHEIM	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	Oct, 2029 (6 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (10 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (10 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Do you want to check out GLYXAMBI patents from before 2022?

Exclusivity	Exclusivity Expiration
M (M)	Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...

Dosage: TABLET;ORAL